On 1 March 2022, all people using Humira were automatically issued with an initial Special Authority number for Amgevita. Although this number expired on 31 July 2022, it can still be renewed.
All Humira Special Authority numbers expired on 1 October 2022 and the preferred funded adalimumab option is now the biosimilar medicine, Amgevita. However, if a waiver for a patient to remain on Humira was submitted and approved before 1 October, this will not be cancelled.
If you haven’t yet moved your patient from Humira to Amgevita you should:
- Discuss with the patient the continuation of their adalimumab treatment using Amgevita
- Complete an Amgevita Special Authority renewal application based on the patient's current clinical condition on adalimumab (either Humira or Amgevita).
Some patients who were on Humira prior to 1 March 2022, may be able to remain on Humira. It is only funded for patients previously treated with Humira who, following discussion with their prescriber:
- have Crohn’s disease or ocular inflammation and are considered at risk of disease destabilisation if there were to be any change to their treatment regimen.
- trial Amgevita and experience clinical difficulties (intolerable side effects or loss of disease control) and wish to return to Humira.
If your patient is eligible to continue with Humira you should:
- Complete a new initial Special Authority form for Humira for the appropriate indication (unless a waiver to remain on Humira was submitted and approved before 1 October, in which case it will remain valid).
Amgevita Special Authorities are valid for two years.